# Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma

> **NCT07688252** · PHASE1 · RECRUITING · sponsor: **Chang Gung Memorial Hospital** · enrollment: 30 (estimated)

## Conditions studied

- High Risk Neuroblastoma

## Interventions

- **BIOLOGICAL:** Dinutuximab Beta
- **DRUG:** Induction chemotherapy

## Key facts

- **NCT ID:** NCT07688252
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2032-12-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07688252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07688252, "Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07688252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*